ascopost.com

Backlink analytics and domain authority

Backlinks

All Dofollow Nofollow UGC DR ▾ Ref. domains ▾ + Add filter

50 backlinks All New Lost

Referring page	DR	Ref. domains	Linked domains	Anchor and target URL
News \| Immunology \| Stanford Medicine https://med.stanford.edu/immunol/news.html?main_panel_builder_2055537194_panel_1_panel_builder_1020572331_panel_0_external_news_contai_start=5&main_panel_builder_2055537194_panel_1_panel_builder_1502380965_panel_0_external_news_contai_start=5&main_panel_builder_2055537194_panel_1_panel_builder_1992353054_panel_0_external_news_contai_534287100_start=10&main_panel_builder_2055537194_panel_1_panel_builder_1992353054_panel_0_external_news_contai_572495308_start=5&main_panel_builder_2055537194_panel_1_panel_buil med.stanford.edu	82	2,806	1,516	Risk of Secondary Cancer After CAR T-Cell Therapy https://ascopost.com/news/june-2024/risk-of-secondary-cancer-after-car-t-cell-therapy DOFOLLOW
News \| Immunology \| Stanford Medicine https://med.stanford.edu/immunol/news.html?main_panel_builder_2055537194_panel_1_panel_builder_1020572331_panel_0_external_news_contai_start=5&main_panel_builder_2055537194_panel_1_panel_builder_1502380965_panel_0_external_news_contai_start=5&main_panel_builder_2055537194_panel_1_panel_builder_1992353054_panel_0_external_news_contai_534287100_start=15&main_panel_builder_2055537194_panel_1_panel_builder_1992353054_panel_0_external_news_contai_572495308_start=5&main_panel_builder_2055537194_panel_1_panel_buil med.stanford.edu	82	2,806	1,516	Risk of Secondary Cancer After CAR T-Cell Therapy https://ascopost.com/news/june-2024/risk-of-secondary-cancer-after-car-t-cell-therapy DOFOLLOW
News \| Immunology \| Stanford Medicine https://med.stanford.edu/immunol/news.html?main_panel_builder_2055537194_panel_1_panel_builder_1992353054_panel_0_external_news_contai_534287100_start=20&main_panel_builder_2055537194_panel_1_panel_builder_1992353054_panel_0_external_news_contai_572495308_start=5&main_panel_builder_2055537194_panel_1_panel_builder_1992353054_panel_0_external_news_contai_727345393_start=5&main_panel_builder_2055537194_panel_1_panel_builder_1992353054_panel_0_external_news_contai_742174239_start=5&main_panel_builder_205553719 med.stanford.edu	82	2,806	1,516	Risk of Secondary Cancer After CAR T-Cell Therapy https://ascopost.com/news/june-2024/risk-of-secondary-cancer-after-car-t-cell-therapy DOFOLLOW
News \| Immunology \| Stanford Medicine https://med.stanford.edu/immunol/news.html?main_panel_builder_2055537194_panel_1_panel_builder_1020572331_panel_0_external_news_contai_start=10&main_panel_builder_2055537194_panel_1_panel_builder_1992353054_panel_0_external_news_contai_534287100_start=10&main_panel_builder_2055537194_panel_1_panel_builder_1992353054_panel_0_external_news_contai_727345393_start=10&main_panel_builder_2055537194_panel_1_panel_builder_1992353054_panel_0_external_news_contai_742174239_start=10&main_panel_builder_2055537194_panel med.stanford.edu	82	2,806	1,516	Risk of Secondary Cancer After CAR T-Cell Therapy https://ascopost.com/news/june-2024/risk-of-secondary-cancer-after-car-t-cell-therapy DOFOLLOW
news.html https://med.stanford.edu/immunol/news.html?main_panel_builder_2055537194_panel_1_panel_builder_1992353054_panel_0_external_news_contai_534287100_start=5&main_panel_builder_2055537194_panel_1_panel_builder_1992353054_panel_0_external_news_contai_572495308_start=0&main_panel_builder_2055537194_panel_1_panel_builder_1992353054_panel_0_external_news_contai_727345393_start=5&main_panel_builder_2055537194_panel_1_panel_builder_1992353054_panel_0_external_news_contai_742174239_start=0&main_panel_builder_2055537194 med.stanford.edu	82	2,806	1,516	Risk of Secondary Cancer After CAR T-Cell Therapy https://ascopost.com/news/june-2024/risk-of-secondary-cancer-after-car-t-cell-therapy DOFOLLOW
News \| Immunology \| Stanford Medicine https://med.stanford.edu/immunol/news.html?main_panel_builder_2055537194_panel_1_panel_builder_1020572331_panel_0_external_news_contai_start=5&main_panel_builder_2055537194_panel_1_panel_builder_1502380965_panel_0_external_news_contai_start=0&main_panel_builder_2055537194_panel_1_panel_builder_1992353054_panel_0_external_news_contai_572495308_start=5&main_panel_builder_2055537194_panel_1_panel_builder_1992353054_panel_0_external_news_contai_727345393_start=5&main_panel_builder_2055537194_panel_1_panel_build med.stanford.edu	82	2,806	1,516	Risk of Secondary Cancer After CAR T-Cell Therapy https://ascopost.com/news/june-2024/risk-of-secondary-cancer-after-car-t-cell-therapy DOFOLLOW
New Medical Malpractice Rules Issued by American Law Institute \| Conexiant https://conexiant.com/cardiology/ViewArticle?id=8b1df8e7-eaa5-40ca-8025-b52a5a9a8aa1 conexiant.com	71	31	310	The ASCO Post https://ascopost.com/ DOFOLLOW
News \| Immunology \| Stanford Medicine https://med.stanford.edu/immunol/news.html?main_panel_builder_2055537194_panel_1_panel_builder_1020572331_panel_0_external_news_contai_start=5&main_panel_builder_2055537194_panel_1_panel_builder_1992353054_panel_0_external_news_contai_534287100_start=10&main_panel_builder_2055537194_panel_1_panel_builder_1992353054_panel_0_external_news_contai_572495308_start=5&main_panel_builder_2055537194_panel_1_panel_builder_1992353054_panel_0_external_news_contai_727345393_start=0&main_panel_builder_2055537194_panel_1_ med.stanford.edu	82	2,806	1,516	Risk of Secondary Cancer After CAR T-Cell Therapy https://ascopost.com/news/june-2024/risk-of-secondary-cancer-after-car-t-cell-therapy DOFOLLOW
News \| Immunology \| Stanford Medicine https://med.stanford.edu/immunol/news.html?main_panel_builder_2055537194_panel_1_panel_builder_1020572331_panel_0_external_news_contai_start=10&main_panel_builder_2055537194_panel_1_panel_builder_1992353054_panel_0_external_news_contai_534287100_start=5&main_panel_builder_2055537194_panel_1_panel_builder_1992353054_panel_0_external_news_contai_572495308_start=5&main_panel_builder_2055537194_panel_1_panel_builder_1992353054_panel_0_external_news_contai_727345393_start=5&main_panel_builder_2055537194_panel_1_ med.stanford.edu	82	2,806	1,516	Risk of Secondary Cancer After CAR T-Cell Therapy https://ascopost.com/news/june-2024/risk-of-secondary-cancer-after-car-t-cell-therapy DOFOLLOW
News \| Immunology \| Stanford Medicine https://med.stanford.edu/immunol/news.html?main_panel_builder_2055537194_panel_1_panel_builder_1992353054_panel_0_external_news_contai_534287100_start=0&main_panel_builder_2055537194_panel_1_panel_builder_1992353054_panel_0_external_news_contai_572495308_start=10&main_panel_builder_2055537194_panel_1_panel_builder_1992353054_panel_0_external_news_contai_727345393_start=0&main_panel_builder_2055537194_panel_1_panel_builder_1992353054_panel_0_external_news_contai_742174239_start=10&main_panel_builder_20555371 med.stanford.edu	82	2,806	1,516	Risk of Secondary Cancer After CAR T-Cell Therapy https://ascopost.com/news/june-2024/risk-of-secondary-cancer-after-car-t-cell-therapy DOFOLLOW
News \| Immunology \| Stanford Medicine https://med.stanford.edu/immunol/news.html?main_panel_builder_2055537194_panel_1_panel_builder_1992353054_panel_0_external_news_contai_534287100_start=0&main_panel_builder_2055537194_panel_1_panel_builder_1992353054_panel_0_external_news_contai_727345393_start=15&main_panel_builder_2055537194_panel_1_panel_builder_1992353054_panel_0_external_news_contai_742174239_start=5&main_panel_builder_2055537194_panel_1_panel_builder_1992353054_panel_0_external_news_contai_start=0&main_panel_builder_2055537194_panel_1_ med.stanford.edu	82	2,806	1,516	Risk of Secondary Cancer After CAR T-Cell Therapy https://ascopost.com/news/june-2024/risk-of-secondary-cancer-after-car-t-cell-therapy DOFOLLOW
news.html https://med.stanford.edu/immunol/news.html?main_panel_builder_2055537194_panel_1_panel_builder_1992353054_panel_0_external_news_contai_534287100_start=5&main_panel_builder_2055537194_panel_1_panel_builder_1992353054_panel_0_external_news_contai_727345393_start=5&main_panel_builder_2055537194_panel_1_panel_builder_1992353054_panel_0_external_news_contai_742174239_start=5&main_panel_builder_2055537194_panel_1_panel_builder_1992353054_panel_0_external_news_contai_start=10&main_panel_builder_2055537194_panel_1_ med.stanford.edu	82	2,806	1,516	Risk of Secondary Cancer After CAR T-Cell Therapy https://ascopost.com/news/june-2024/risk-of-secondary-cancer-after-car-t-cell-therapy DOFOLLOW
News \| Immunology \| Stanford Medicine https://med.stanford.edu/immunol/news.html?main_panel_builder_2055537194_panel_1_panel_builder_1020572331_panel_0_external_news_contai_start=5&main_panel_builder_2055537194_panel_1_panel_builder_1502380965_panel_0_external_news_contai_start=0&main_panel_builder_2055537194_panel_1_panel_builder_1992353054_panel_0_external_news_contai_727345393_start=0&main_panel_builder_2055537194_panel_1_panel_builder_1992353054_panel_0_external_news_contai_742174239_start=0&main_panel_builder_2055537194_panel_1_panel_build med.stanford.edu	82	2,806	1,516	Risk of Secondary Cancer After CAR T-Cell Therapy https://ascopost.com/news/june-2024/risk-of-secondary-cancer-after-car-t-cell-therapy DOFOLLOW
News \| Immunology \| Stanford Medicine https://med.stanford.edu/immunol/news.html?main_panel_builder_2055537194_panel_1_panel_builder_1020572331_panel_0_external_news_contai_start=10&main_panel_builder_2055537194_panel_1_panel_builder_1502380965_panel_0_external_news_contai_start=5&main_panel_builder_2055537194_panel_1_panel_builder_1992353054_panel_0_external_news_contai_534287100_start=5&main_panel_builder_2055537194_panel_1_panel_builder_1992353054_panel_0_external_news_contai_742174239_start=5&main_panel_builder_2055537194_panel_1_panel_buil med.stanford.edu	82	2,806	1,516	Risk of Secondary Cancer After CAR T-Cell Therapy https://ascopost.com/news/june-2024/risk-of-secondary-cancer-after-car-t-cell-therapy DOFOLLOW
News \| Immunology \| Stanford Medicine https://med.stanford.edu/immunol/news.html?main_panel_builder_2055537194_panel_1_panel_builder_1020572331_panel_0_external_news_contai_start=10&main_panel_builder_2055537194_panel_1_panel_builder_1992353054_panel_0_external_news_contai_534287100_start=5&main_panel_builder_2055537194_panel_1_panel_builder_1992353054_panel_0_external_news_contai_727345393_start=10&main_panel_builder_2055537194_panel_1_panel_builder_1992353054_panel_0_external_news_contai_742174239_start=5 med.stanford.edu	82	2,806	1,516	Risk of Secondary Cancer After CAR T-Cell Therapy https://ascopost.com/news/june-2024/risk-of-secondary-cancer-after-car-t-cell-therapy DOFOLLOW
News \| Immunology \| Stanford Medicine https://med.stanford.edu/immunol/news.html?main_panel_builder_2055537194_panel_1_panel_builder_1020572331_panel_0_external_news_contai_start=5&main_panel_builder_2055537194_panel_1_panel_builder_1992353054_panel_0_external_news_contai_534287100_start=10&main_panel_builder_2055537194_panel_1_panel_builder_1992353054_panel_0_external_news_contai_572495308_start=15&main_panel_builder_2055537194_panel_1_panel_builder_1992353054_panel_0_external_news_contai_742174239_start=5&main_panel_builder_2055537194_panel_1 med.stanford.edu	82	2,806	1,516	Risk of Secondary Cancer After CAR T-Cell Therapy https://ascopost.com/news/june-2024/risk-of-secondary-cancer-after-car-t-cell-therapy DOFOLLOW
News \| Immunology \| Stanford Medicine https://med.stanford.edu/immunol/news.html?main_panel_builder_2055537194_panel_1_panel_builder_1020572331_panel_0_external_news_contai_start=5&main_panel_builder_2055537194_panel_1_panel_builder_1992353054_panel_0_external_news_contai_534287100_start=5&main_panel_builder_2055537194_panel_1_panel_builder_1992353054_panel_0_external_news_contai_727345393_start=0&main_panel_builder_2055537194_panel_1_panel_builder_1992353054_panel_0_external_news_contai_742174239_start=10&main_panel_builder_2055537194_panel_1_ med.stanford.edu	82	2,806	1,516	Risk of Secondary Cancer After CAR T-Cell Therapy https://ascopost.com/news/june-2024/risk-of-secondary-cancer-after-car-t-cell-therapy DOFOLLOW
News \| Immunology \| Stanford Medicine https://med.stanford.edu/immunol/news.html?main_panel_builder_2055537194_panel_1_panel_builder_1020572331_panel_0_external_news_contai_start=5&main_panel_builder_2055537194_panel_1_panel_builder_1502380965_panel_0_external_news_contai_start=0&main_panel_builder_2055537194_panel_1_panel_builder_1992353054_panel_0_external_news_contai_534287100_start=5&main_panel_builder_2055537194_panel_1_panel_builder_1992353054_panel_0_external_news_contai_572495308_start=5&main_panel_builder_2055537194_panel_1_panel_build med.stanford.edu	82	2,806	1,516	Risk of Secondary Cancer After CAR T-Cell Therapy https://ascopost.com/news/june-2024/risk-of-secondary-cancer-after-car-t-cell-therapy DOFOLLOW
News \| Immunology \| Stanford Medicine https://med.stanford.edu/immunol/news.html?main_panel_builder_2055537194_panel_1_panel_builder_1020572331_panel_0_external_news_contai_start=0&main_panel_builder_2055537194_panel_1_panel_builder_1992353054_panel_0_external_news_contai_534287100_start=0&main_panel_builder_2055537194_panel_1_panel_builder_1992353054_panel_0_external_news_contai_727345393_start=5&main_panel_builder_2055537194_panel_1_panel_builder_1992353054_panel_0_external_news_contai_742174239_start=0&main_panel_builder_2055537194_panel_1_p med.stanford.edu	82	2,806	1,516	Risk of Secondary Cancer After CAR T-Cell Therapy https://ascopost.com/news/june-2024/risk-of-secondary-cancer-after-car-t-cell-therapy DOFOLLOW
News \| Immunology \| Stanford Medicine https://med.stanford.edu/immunol/news.html?main_panel_builder_2055537194_panel_1_panel_builder_1020572331_panel_0_external_news_contai_start=5&main_panel_builder_2055537194_panel_1_panel_builder_1502380965_panel_0_external_news_contai_start=5&main_panel_builder_2055537194_panel_1_panel_builder_1992353054_panel_0_external_news_contai_572495308_start=10&main_panel_builder_2055537194_panel_1_panel_builder_1992353054_panel_0_external_news_contai_727345393_start=0&main_panel_builder_2055537194_panel_1_panel_buil med.stanford.edu	82	2,806	1,516	Risk of Secondary Cancer After CAR T-Cell Therapy https://ascopost.com/news/june-2024/risk-of-secondary-cancer-after-car-t-cell-therapy DOFOLLOW
News \| Immunology \| Stanford Medicine https://med.stanford.edu/immunol/news.html?main_panel_builder_2055537194_panel_1_panel_builder_1020572331_panel_0_external_news_contai_start=5&main_panel_builder_2055537194_panel_1_panel_builder_1502380965_panel_0_external_news_contai_start=0&main_panel_builder_2055537194_panel_1_panel_builder_1992353054_panel_0_external_news_contai_534287100_start=0&main_panel_builder_2055537194_panel_1_panel_builder_1992353054_panel_0_external_news_contai_727345393_start=5&main_panel_builder_2055537194_panel_1_panel_build med.stanford.edu	82	2,806	1,516	Risk of Secondary Cancer After CAR T-Cell Therapy https://ascopost.com/news/june-2024/risk-of-secondary-cancer-after-car-t-cell-therapy DOFOLLOW
Вакцинация от ВПЧ: свежие данные и перспективы, эффективность вакцины против ... https://protiv-raka.ru/analytics/vakczinacziya-protiv-vpch-svezhie-dannye-i-perspektivy protiv-raka.ru	60	9	143	SGO https://ascopost.com/issues/march-25-2021/sgo-and-fwc-issue-joint-statement-on-the-elimination-of-hpv DOFOLLOW
News \| Immunology \| Stanford Medicine https://med.stanford.edu/immunol/news.html?main_panel_builder_2055537194_panel_1_panel_builder_1020572331_panel_0_external_news_contai_start=0&main_panel_builder_2055537194_panel_1_panel_builder_1502380965_panel_0_external_news_contai_start=0&main_panel_builder_2055537194_panel_1_panel_builder_1992353054_panel_0_external_news_contai_572495308_start=15&main_panel_builder_2055537194_panel_1_panel_builder_1992353054_panel_0_external_news_contai_727345393_start=0&main_panel_builder_2055537194_panel_1_panel_buil med.stanford.edu	82	2,806	1,516	Risk of Secondary Cancer After CAR T-Cell Therapy https://ascopost.com/news/june-2024/risk-of-secondary-cancer-after-car-t-cell-therapy DOFOLLOW
Bone Density \| Conexiant https://www.conexiant.com/radiology/topics-and-conditions/bone-density conexiant.com	71	31	310	The ASCO Post https://ascopost.com/ DOFOLLOW
News \| Immunology \| Stanford Medicine https://med.stanford.edu/immunol/news.html?main_panel_builder_2055537194_panel_1_panel_builder_1020572331_panel_0_external_news_contai_start=5&main_panel_builder_2055537194_panel_1_panel_builder_1992353054_panel_0_external_news_contai_534287100_start=5&main_panel_builder_2055537194_panel_1_panel_builder_1992353054_panel_0_external_news_contai_727345393_start=5&main_panel_builder_2055537194_panel_1_panel_builder_1992353054_panel_0_external_news_contai_742174239_start=0&main_panel_builder_2055537194_panel_1_p med.stanford.edu	82	2,806	1,516	Risk of Secondary Cancer After CAR T-Cell Therapy https://ascopost.com/news/june-2024/risk-of-secondary-cancer-after-car-t-cell-therapy DOFOLLOW
News \| Immunology \| Stanford Medicine https://med.stanford.edu/immunol/news.html?main_panel_builder_2055537194_panel_1_panel_builder_1992353054_panel_0_external_news_contai_534287100_start=15&main_panel_builder_2055537194_panel_1_panel_builder_1992353054_panel_0_external_news_contai_727345393_start=0&main_panel_builder_2055537194_panel_1_panel_builder_1992353054_panel_0_external_news_contai_742174239_start=10&main_panel_builder_2055537194_panel_1_panel_builder_1992353054_panel_0_external_news_contai_start=5&main_panel_builder_2055537194_panel_1 med.stanford.edu	82	2,806	1,516	Risk of Secondary Cancer After CAR T-Cell Therapy https://ascopost.com/news/june-2024/risk-of-secondary-cancer-after-car-t-cell-therapy DOFOLLOW
News \| Immunology \| Stanford Medicine https://med.stanford.edu/immunol/news.html?main_panel_builder_2055537194_panel_1_panel_builder_1992353054_panel_0_external_news_contai_534287100_start=5&main_panel_builder_2055537194_panel_1_panel_builder_1992353054_panel_0_external_news_contai_572495308_start=15&main_panel_builder_2055537194_panel_1_panel_builder_1992353054_panel_0_external_news_contai_727345393_start=0&main_panel_builder_2055537194_panel_1_panel_builder_1992353054_panel_0_external_news_contai_742174239_start=10&main_panel_builder_20555371 med.stanford.edu	82	2,806	1,516	Risk of Secondary Cancer After CAR T-Cell Therapy https://ascopost.com/news/june-2024/risk-of-secondary-cancer-after-car-t-cell-therapy DOFOLLOW
News \| Immunology \| Stanford Medicine https://med.stanford.edu/immunol/news.html?main_panel_builder_2055537194_panel_1_panel_builder_1020572331_panel_0_external_news_contai_start=15&main_panel_builder_2055537194_panel_1_panel_builder_1992353054_panel_0_external_news_contai_534287100_start=5&main_panel_builder_2055537194_panel_1_panel_builder_1992353054_panel_0_external_news_contai_727345393_start=10&main_panel_builder_2055537194_panel_1_panel_builder_1992353054_panel_0_external_news_contai_742174239_start=10&main_panel_builder_2055537194_panel_ med.stanford.edu	82	2,806	1,516	Risk of Secondary Cancer After CAR T-Cell Therapy https://ascopost.com/news/june-2024/risk-of-secondary-cancer-after-car-t-cell-therapy DOFOLLOW
Beta-Blockers Following MI: Still Needed? \| Conexiant https://conexiant.com/cardiology/articles/beta-blockers-following-mi-still-needed conexiant.com	71	31	310	The ASCO Post https://ascopost.com/ DOFOLLOW
News \| Immunology \| Stanford Medicine https://med.stanford.edu/immunol/news.html?main_panel_builder_2055537194_panel_1_panel_builder_1020572331_panel_0_external_news_contai_start=5&main_panel_builder_2055537194_panel_1_panel_builder_1992353054_panel_0_external_news_contai_534287100_start=15&main_panel_builder_2055537194_panel_1_panel_builder_1992353054_panel_0_external_news_contai_572495308_start=5&main_panel_builder_2055537194_panel_1_panel_builder_1992353054_panel_0_external_news_contai_727345393_start=5&main_panel_builder_2055537194_panel_1_ med.stanford.edu	82	2,806	1,516	Risk of Secondary Cancer After CAR T-Cell Therapy https://ascopost.com/news/june-2024/risk-of-secondary-cancer-after-car-t-cell-therapy DOFOLLOW
News \| Immunology \| Stanford Medicine https://med.stanford.edu/immunol/news.html?main_panel_builder_2055537194_panel_1_panel_builder_1020572331_panel_0_external_news_contai_start=0&main_panel_builder_2055537194_panel_1_panel_builder_1992353054_panel_0_external_news_contai_534287100_start=15&main_panel_builder_2055537194_panel_1_panel_builder_1992353054_panel_0_external_news_contai_727345393_start=5&main_panel_builder_2055537194_panel_1_panel_builder_1992353054_panel_0_external_news_contai_742174239_start=10&main_panel_builder_2055537194_panel_1 med.stanford.edu	82	2,806	1,516	Risk of Secondary Cancer After CAR T-Cell Therapy https://ascopost.com/news/june-2024/risk-of-secondary-cancer-after-car-t-cell-therapy DOFOLLOW
News \| Immunology \| Stanford Medicine https://med.stanford.edu/immunol/news.html?main_panel_builder_2055537194_panel_1_panel_builder_1020572331_panel_0_external_news_contai_start=10&main_panel_builder_2055537194_panel_1_panel_builder_1502380965_panel_0_external_news_contai_start=0&main_panel_builder_2055537194_panel_1_panel_builder_1992353054_panel_0_external_news_contai_534287100_start=5&main_panel_builder_2055537194_panel_1_panel_builder_1992353054_panel_0_external_news_contai_727345393_start=0&main_panel_builder_2055537194_panel_1_panel_buil med.stanford.edu	82	2,806	1,516	Risk of Secondary Cancer After CAR T-Cell Therapy https://ascopost.com/news/june-2024/risk-of-secondary-cancer-after-car-t-cell-therapy DOFOLLOW
News \| Immunology \| Stanford Medicine https://med.stanford.edu/immunol/news.html?main_panel_builder_2055537194_panel_1_panel_builder_1020572331_panel_0_external_news_contai_start=5&main_panel_builder_2055537194_panel_1_panel_builder_1992353054_panel_0_external_news_contai_534287100_start=5&main_panel_builder_2055537194_panel_1_panel_builder_1992353054_panel_0_external_news_contai_572495308_start=5&main_panel_builder_2055537194_panel_1_panel_builder_1992353054_panel_0_external_news_contai_727345393_start=15&main_panel_builder_2055537194_panel_1_ med.stanford.edu	82	2,806	1,516	Risk of Secondary Cancer After CAR T-Cell Therapy https://ascopost.com/news/june-2024/risk-of-secondary-cancer-after-car-t-cell-therapy DOFOLLOW
News \| Immunology \| Stanford Medicine https://med.stanford.edu/immunol/news.html?main_panel_builder_2055537194_panel_1_panel_builder_1020572331_panel_0_external_news_contai_start=10&main_panel_builder_2055537194_panel_1_panel_builder_1992353054_panel_0_external_news_contai_534287100_start=5&main_panel_builder_2055537194_panel_1_panel_builder_1992353054_panel_0_external_news_contai_742174239_start=5&main_panel_builder_2055537194_panel_1_panel_builder_1992353054_panel_0_external_news_contai_start=10&main_panel_builder_2055537194_panel_1_panel_bui med.stanford.edu	82	2,806	1,516	Risk of Secondary Cancer After CAR T-Cell Therapy https://ascopost.com/news/june-2024/risk-of-secondary-cancer-after-car-t-cell-therapy DOFOLLOW
News \| Immunology \| Stanford Medicine https://med.stanford.edu/immunol/news.html?main_panel_builder_2055537194_panel_1_panel_builder_1502380965_panel_0_external_news_contai_start=5&main_panel_builder_2055537194_panel_1_panel_builder_1992353054_panel_0_external_news_contai_534287100_start=5&main_panel_builder_2055537194_panel_1_panel_builder_1992353054_panel_0_external_news_contai_572495308_start=0&main_panel_builder_2055537194_panel_1_panel_builder_1992353054_panel_0_external_news_contai_727345393_start=5&main_panel_builder_2055537194_panel_1_p med.stanford.edu	82	2,806	1,516	Risk of Secondary Cancer After CAR T-Cell Therapy https://ascopost.com/news/june-2024/risk-of-secondary-cancer-after-car-t-cell-therapy DOFOLLOW
News \| Immunology \| Stanford Medicine https://med.stanford.edu/immunol/news.html?main_panel_builder_2055537194_panel_1_panel_builder_1502380965_panel_0_external_news_contai_start=0&main_panel_builder_2055537194_panel_1_panel_builder_1992353054_panel_0_external_news_contai_534287100_start=0&main_panel_builder_2055537194_panel_1_panel_builder_1992353054_panel_0_external_news_contai_572495308_start=10&main_panel_builder_2055537194_panel_1_panel_builder_1992353054_panel_0_external_news_contai_727345393_start=5&main_panel_builder_2055537194_panel_1_ med.stanford.edu	82	2,806	1,516	Risk of Secondary Cancer After CAR T-Cell Therapy https://ascopost.com/news/june-2024/risk-of-secondary-cancer-after-car-t-cell-therapy DOFOLLOW
News \| Immunology \| Stanford Medicine https://med.stanford.edu/immunol/news.html?main_panel_builder_2055537194_panel_1_panel_builder_1502380965_panel_0_external_news_contai_start=0&main_panel_builder_2055537194_panel_1_panel_builder_1992353054_panel_0_external_news_contai_534287100_start=0&main_panel_builder_2055537194_panel_1_panel_builder_1992353054_panel_0_external_news_contai_572495308_start=10&main_panel_builder_2055537194_panel_1_panel_builder_1992353054_panel_0_external_news_contai_727345393_start=5&main_panel_builder_2055537194_panel_1_ med.stanford.edu	82	2,806	1,516	Risk of Secondary Cancer After CAR T-Cell Therapy https://ascopost.com/news/june-2024/risk-of-secondary-cancer-after-car-t-cell-therapy DOFOLLOW
News \| Immunology \| Stanford Medicine https://med.stanford.edu/immunol/news.html?main_panel_builder_2055537194_panel_1_panel_builder_1992353054_panel_0_external_news_contai_534287100_start=15&main_panel_builder_2055537194_panel_1_panel_builder_1992353054_panel_0_external_news_contai_572495308_start=10&main_panel_builder_2055537194_panel_1_panel_builder_1992353054_panel_0_external_news_contai_727345393_start=5&main_panel_builder_2055537194_panel_1_panel_builder_1992353054_panel_0_external_news_contai_742174239_start=5&main_panel_builder_20555371 med.stanford.edu	82	2,806	1,516	Risk of Secondary Cancer After CAR T-Cell Therapy https://ascopost.com/news/june-2024/risk-of-secondary-cancer-after-car-t-cell-therapy DOFOLLOW
News \| Immunology \| Stanford Medicine https://med.stanford.edu/immunol/news.html?main_panel_builder_2055537194_panel_1_panel_builder_1992353054_panel_0_external_news_contai_572495308_start=10&main_panel_builder_2055537194_panel_1_panel_builder_1992353054_panel_0_external_news_contai_742174239_start=0&main_panel_builder_2055537194_panel_1_panel_builder_1992353054_panel_0_external_news_contai_start=0&main_panel_builder_2055537194_panel_1_panel_builder_panel_0_external_news_contai_start=5 med.stanford.edu	82	2,806	1,516	Risk of Secondary Cancer After CAR T-Cell Therapy https://ascopost.com/news/june-2024/risk-of-secondary-cancer-after-car-t-cell-therapy DOFOLLOW
News \| Immunology \| Stanford Medicine https://med.stanford.edu/immunol/news.html?main_panel_builder_2055537194_panel_1_panel_builder_1020572331_panel_0_external_news_contai_start=5&main_panel_builder_2055537194_panel_1_panel_builder_1502380965_panel_0_external_news_contai_start=5&main_panel_builder_2055537194_panel_1_panel_builder_1992353054_panel_0_external_news_contai_534287100_start=5&main_panel_builder_2055537194_panel_1_panel_builder_1992353054_panel_0_external_news_contai_727345393_start=0&main_panel_builder_2055537194_panel_1_panel_build med.stanford.edu	82	2,806	1,516	Risk of Secondary Cancer After CAR T-Cell Therapy https://ascopost.com/news/june-2024/risk-of-secondary-cancer-after-car-t-cell-therapy DOFOLLOW
News \| Immunology \| Stanford Medicine https://med.stanford.edu/immunol/news.html?main_panel_builder_2055537194_panel_1_panel_builder_1502380965_panel_0_external_news_contai_start=5&main_panel_builder_2055537194_panel_1_panel_builder_1992353054_panel_0_external_news_contai_534287100_start=5&main_panel_builder_2055537194_panel_1_panel_builder_1992353054_panel_0_external_news_contai_572495308_start=0&main_panel_builder_2055537194_panel_1_panel_builder_1992353054_panel_0_external_news_contai_727345393_start=5&main_panel_builder_2055537194_panel_1_p med.stanford.edu	82	2,806	1,516	Risk of Secondary Cancer After CAR T-Cell Therapy https://ascopost.com/news/june-2024/risk-of-secondary-cancer-after-car-t-cell-therapy DOFOLLOW
News \| Immunology \| Stanford Medicine https://med.stanford.edu/immunol/news.html?main_panel_builder_2055537194_panel_1_panel_builder_1020572331_panel_0_external_news_contai_start=5&main_panel_builder_2055537194_panel_1_panel_builder_1502380965_panel_0_external_news_contai_start=5&main_panel_builder_2055537194_panel_1_panel_builder_1992353054_panel_0_external_news_contai_534287100_start=10&main_panel_builder_2055537194_panel_1_panel_builder_1992353054_panel_0_external_news_contai_727345393_start=15&main_panel_builder_2055537194_panel_1_panel_bui med.stanford.edu	82	2,806	1,516	Risk of Secondary Cancer After CAR T-Cell Therapy https://ascopost.com/news/june-2024/risk-of-secondary-cancer-after-car-t-cell-therapy DOFOLLOW
News \| Immunology \| Stanford Medicine https://med.stanford.edu/immunol/news.html?main_panel_builder_2055537194_panel_1_panel_builder_1020572331_panel_0_external_news_contai_start=0&main_panel_builder_2055537194_panel_1_panel_builder_1502380965_panel_0_external_news_contai_start=5&main_panel_builder_2055537194_panel_1_panel_builder_1992353054_panel_0_external_news_contai_534287100_start=5&main_panel_builder_2055537194_panel_1_panel_builder_1992353054_panel_0_external_news_contai_572495308_start=5&main_panel_builder_2055537194_panel_1_panel_build med.stanford.edu	82	2,806	1,516	Risk of Secondary Cancer After CAR T-Cell Therapy https://ascopost.com/news/june-2024/risk-of-secondary-cancer-after-car-t-cell-therapy DOFOLLOW
News \| Immunology \| Stanford Medicine https://med.stanford.edu/immunol/news.html?main_panel_builder_2055537194_panel_1_panel_builder_1020572331_panel_0_external_news_contai_start=5&main_panel_builder_2055537194_panel_1_panel_builder_1992353054_panel_0_external_news_contai_534287100_start=5&main_panel_builder_2055537194_panel_1_panel_builder_1992353054_panel_0_external_news_contai_572495308_start=15&main_panel_builder_2055537194_panel_1_panel_builder_1992353054_panel_0_external_news_contai_727345393_start=15&main_panel_builder_2055537194_panel_1 med.stanford.edu	82	2,806	1,516	Risk of Secondary Cancer After CAR T-Cell Therapy https://ascopost.com/news/june-2024/risk-of-secondary-cancer-after-car-t-cell-therapy DOFOLLOW
News \| Immunology \| Stanford Medicine https://med.stanford.edu/immunol/news.html?main_panel_builder_2055537194_panel_1_panel_builder_1020572331_panel_0_external_news_contai_start=5&main_panel_builder_2055537194_panel_1_panel_builder_1992353054_panel_0_external_news_contai_534287100_start=0&main_panel_builder_2055537194_panel_1_panel_builder_1992353054_panel_0_external_news_contai_727345393_start=10&main_panel_builder_2055537194_panel_1_panel_builder_1992353054_panel_0_external_news_contai_742174239_start=0&main_panel_builder_2055537194_panel_1_ med.stanford.edu	82	2,806	1,516	Risk of Secondary Cancer After CAR T-Cell Therapy https://ascopost.com/news/june-2024/risk-of-secondary-cancer-after-car-t-cell-therapy DOFOLLOW
News \| Immunology \| Stanford Medicine https://med.stanford.edu/immunol/news.html?main_panel_builder_2055537194_panel_1_panel_builder_1502380965_panel_0_external_news_contai_start=0&main_panel_builder_2055537194_panel_1_panel_builder_1992353054_panel_0_external_news_contai_534287100_start=10&main_panel_builder_2055537194_panel_1_panel_builder_1992353054_panel_0_external_news_contai_727345393_start=5&main_panel_builder_2055537194_panel_1_panel_builder_1992353054_panel_0_external_news_contai_742174239_start=0&main_panel_builder_2055537194_panel_1_ med.stanford.edu	82	2,806	1,516	Risk of Secondary Cancer After CAR T-Cell Therapy https://ascopost.com/news/june-2024/risk-of-secondary-cancer-after-car-t-cell-therapy DOFOLLOW
When to Treat First in Metastatic NSCLC? \| Conexiant https://conexiant.com/family-medicine/ViewArticle?id=f266f2ea-e95a-4615-81fe-1fddd862d75d conexiant.com	71	31	310	The ASCO Post https://ascopost.com/ DOFOLLOW
News \| Immunology \| Stanford Medicine https://med.stanford.edu/immunol/news.html?main_panel_builder_2055537194_panel_1_panel_builder_1992353054_panel_0_external_news_contai_534287100_start=15&main_panel_builder_2055537194_panel_1_panel_builder_1992353054_panel_0_external_news_contai_572495308_start=0&main_panel_builder_2055537194_panel_1_panel_builder_1992353054_panel_0_external_news_contai_727345393_start=0&main_panel_builder_2055537194_panel_1_panel_builder_1992353054_panel_0_external_news_contai_742174239_start=0&main_panel_builder_205553719 med.stanford.edu	82	2,806	1,516	Risk of Secondary Cancer After CAR T-Cell Therapy https://ascopost.com/news/june-2024/risk-of-secondary-cancer-after-car-t-cell-therapy DOFOLLOW
News \| Immunology \| Stanford Medicine https://med.stanford.edu/immunol/news.html?main_panel_builder_2055537194_panel_1_panel_builder_1502380965_panel_0_external_news_contai_start=5&main_panel_builder_2055537194_panel_1_panel_builder_1992353054_panel_0_external_news_contai_534287100_start=5&main_panel_builder_2055537194_panel_1_panel_builder_1992353054_panel_0_external_news_contai_572495308_start=0&main_panel_builder_2055537194_panel_1_panel_builder_1992353054_panel_0_external_news_contai_727345393_start=5&main_panel_builder_2055537194_panel_1_p med.stanford.edu	82	2,806	1,516	Risk of Secondary Cancer After CAR T-Cell Therapy https://ascopost.com/news/june-2024/risk-of-secondary-cancer-after-car-t-cell-therapy DOFOLLOW
News \| Immunology \| Stanford Medicine https://med.stanford.edu/immunol/news.html?main_panel_builder_2055537194_panel_1_panel_builder_1020572331_panel_0_external_news_contai_start=0&main_panel_builder_2055537194_panel_1_panel_builder_1502380965_panel_0_external_news_contai_start=5&main_panel_builder_2055537194_panel_1_panel_builder_1992353054_panel_0_external_news_contai_534287100_start=0&main_panel_builder_2055537194_panel_1_panel_builder_1992353054_panel_0_external_news_contai_572495308_start=5&main_panel_builder_2055537194_panel_1_panel_build med.stanford.edu	82	2,806	1,516	Risk of Secondary Cancer After CAR T-Cell Therapy https://ascopost.com/news/june-2024/risk-of-secondary-cancer-after-car-t-cell-therapy DOFOLLOW

▾

Frequently Asked Questions

How many backlinks does ascopost.com have?

The backlinks page for ascopost.com shows all individual inbound links discovered in our crawl of the web. Each backlink represents a hyperlink on another website that points to a page on ascopost.com. Use the filters to narrow results by dofollow/nofollow status, domain rating, or anchor text.

What is a backlink?

A backlink is a hyperlink on one website that points to a page on a different website. Backlinks are one of the most important ranking factors in search engine algorithms because they act as votes of confidence from other sites. The more high-quality backlinks a domain has, the more authority search engines assign to it.

Are the backlinks to ascopost.com dofollow or nofollow?

Backlinks to ascopost.com include both dofollow and nofollow links. Dofollow links pass link equity (ranking power) to the target site, while nofollow links include a rel="nofollow" attribute that tells search engines not to pass authority. Both types contribute to a natural backlink profile, but dofollow links carry more SEO weight. You can filter by link type using the rel filter above the table.

How often is backlink data updated?

Backlink data is updated monthly when our web crawler completes a new cycle. Our pipeline processes billions of web pages to discover new backlinks, track lost links, and update domain authority scores. The freshness of data depends on when our crawler last visited the referring pages.